Welcome to the healthcare professionals section

In this section, you will find information on RenehaVis™ and its use in knee and hip osteoarthitis (OA).
We have included RenehaVis™ prescribing information, clinical references, a video demonstrating the mechanism of action of RenehaVis™ and other useful information.

If you require further assistance, please contact us.

Shorter time to less pain

A clinical study was conducted studying the effects of RenehaVis™ versus a high molecular weight HA, a low molecular weight HA and placebo. This double blind, placebo controlled, study in Canada showed that patients administered with RenehaVis™ had lower pain scores when walking and at rest compared to the other three arms in the study, notably in a shorter period of time.

RenehaVis patients had the lowest pain score after the 2nd injection and this was maintained for up to 16 weeks.

What is RenehaVis™?

An innovative product for knee and hip OA, RenehaVis™ is the only product on the market that contains 2 Hyaluronic Acids in 1 syringe for a sequential injection.

Chamber 1 contains: Low molecular weight HA – High concentration
Chamber 2 contains: High molecular weight HA – Low concentration

RenehaVis™ offers both patients and doctors the DMC concept: Dual Molecular weight and Concentration concept in a single syringe.

Why different molecular weights and concentrations?

All viscosupplementation products try to help knee OA patients to regain a healthy physiological state of the knee. Low molecular weight Hyaluronic Acid (HA) is known to be able to act as a lubricant in the synovial joint whereas high molecular Hyaluronic Acid (HA) is known for its ability to absorb shocks experienced by the joint.

Low molecular weight HA has 2 other functions:
- It diffuses through the cartilage to protect the chondrocytes (note: a molecule which helps create endogenous HA and proteoglycans) which are commonly destroyed in knee OA patients. This is termed as the "CAGING EFFECT".
- It diffuses to the synoviocytes of the synovial membrane to stimulate production of endogenous HA. This action is known as the MECHANOSENSITIVE EFFECT.

This is why RenehaVis™ has a concentration of low molecular weight HA – to achieve these 3 criteria needed in an OA knee.

The high molecular weight Hyaluronic Acid (HA) is at a lower concentration as it only has 1 function (i.e., shock absorption) as it only has to maintain this function whereas a higher concentration of the low molecular weight HA is provided.

How often is it administered?

Trained Healthcare Practitioners can assess when patients will require re-administration of RenehaVis™ as it depends on the current condition of the disease.

How is it administered?

RenehaVis™ is administered via an intra-articular injection and should only be made by a Healthcare Professional trained in the technique. Care should always be taken to ensure that entry into the synovial capsule is obtained. There are various techniques to do an intra-articular injection. Administration depends greatly on what the patient and the administrator (trained healthcare practitioner) are most comfortable with. Ultrasound - or fluoroscopy - guided injections are recommended especially for intra-articular injection into the hip joint.

How safe is it?

There were no serious adverse events during the clinical study. Non-serious adverse events included pain and local swelling at the injection site (21%), erythema at the injection site (12%), and stiffness in the index knee (7%) amongst all groups.